Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Originally published as JCO Early Release 10.1200/JCO.2007.13.2415 on December 17 2007

Journal of Clinical Oncology, Vol 26, No 3 (January 20), 2008: pp. 455-462
© 2008 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sureda, A.
Right arrow Articles by Schmitz, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sureda, A.
Right arrow Articles by Schmitz, N.

Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Anna Sureda, Stephen Robinson, Carmen Canals, Angelo M. Carella, Marc A. Boogaerts, Dolores Caballero, Ann E. Hunter, Lothar Kanz, Shimon Slavin, Jan J. Cornelissen, Martin Gramatzki, Dietger Niederwieser, Nigel H. Russell, Norbert Schmitz

From the Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Barcelona; Departmento de Hematologia, Hospital Clinico Universitario, Salamanca, Spain; Department of Paediatric Oncology/Bone Marrow Transplantation, Bristol Royal Hospital for Children, Bristol; Department of Haematology, Leicester Royal Infirmary, Leicester; Nottingham City Hospital, Nottingham, United Kingdom; Azienda Ospedaliera Universitaria San Martino, Genoa, Italy; Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium; Medizinische Klinik, Universität Tübingen; Division of Stem Cell Transplantation and Immunotherapy, 2nd Medical Department, University Hospital Schleswig-Holstein Keil Campus, Kiel; Division of Hematology and Oncology, University Hospital Leipzig, Leipzig; Department of Haematology, Asklepios Klinik St Georg, Hamburg, Germany; Blood and Bone Marrow Tansplantation, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; and Erasmus MC-Daniel den Hoed Cancer Center, Rottendam, the Netherlands

Corresponding author: Anna Sureda, MD, Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Antoni Maria i Claret, 167, 08025 Barcelona, Spain; e-mail: asureda{at}santpau.es

Purpose: To compare the clinical outcome in terms of nonrelapse mortality (NRM), relapse rate (RR), overall survival (OS), and progression-free survival (PFS) in patients with relapsed Hodgkin's lymphoma (HL) treated with reduced-intensity conditioning (RIC) or myeloablative conditioning followed by allogeneic stem-cell transplantation (alloSCT).

Patients and Methods: A total of 168 patients with HL undergoing a first alloSCT (RIC, n = 89; myeloablative conditioning, n = 79) between January 1997 and December 2001 and registered in the European Group for Blood and Marrow Transplantation database were analyzed.

Results: NRM was significantly decreased in the RIC group (hazard ratio [HR], 2.85; 95% CI, 1.62 to 5.02; P < .001). OS was better in the RIC group (HR, 2.05; 95% CI, 1.27 to 3.29; P = .04) and there was a trend for better PFS in the RIC group (HR, 1.53; 95% CI, 0.97 to 2.40; P = .07). RR was higher in the RIC group in univariate but not in multivariate analysis. The development of chronic graft-versus-host disease (GVHD) significantly decreased the incidence of relapse, which translated into a trend for a better PFS.

Conclusion: The lower incidence of NRM in the RIC group is encouraging, particularly because these patients experienced adverse pretransplantation characteristics more frequently. This analysis also indicates the existence of a graft-versus-HL effect correlated to the development of GVHD. Additional efforts to reduce the high RR seen in both groups of patients will be necessary to improve the modest PFS (31% v 27%) and OS (59% v 36%) for patients prepared with RIC or myeloablative conditioning.

published online ahead of print at www.jco.org on December 17, 2007.

Presented in part at the 45th Annual Meeting of the American Society of Hematology, December 6-9, 2003, San Diego, CA.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.






About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online